Science
SomaBiome is grounded in peer-reviewed fibromyalgia and microbiome research, including foundational fibromyalgia studies and mechanistic work that support clinical translation.
Research Foundation
- →One-page clinician report
- →Research-stage fibromyalgia likelihood score
- →Prospective validation is the next step
Research Focus
Deep-sequencing of the 600-patient academic cohort.
Utilizing high-resolution metagenomics to identify bacterial taxa specifically enriched or depleted in clinical subjects.
Metagenomic Mapping
Research focused on microbial signatures associated with fibromyalgia and symptom-linked biological patterns relevant to clinical translation.
Scientific Foundation
Fibromyalgia signal (PAIN, 2019):
Species-level microbiome alterations associated with symptom severity.
Fibromyalgia bile-acid / microbiome reinforcement (PAIN, 2022):
Reproducible metabolomic and microbial shifts.
Mechanistic fibromyalgia evidence (Neuron, 2025):
Causal evidence linking microbial functions to sensory processing.
Broader chronic-pain studies informing cross-cohort robustness:
Reproducible microbiome signatures across independent cohorts and geographies.
Selected Publications
Fibromyalgia
PAIN, 2019
Altered microbiome composition in individuals with fibromyalgia
Identified species-level microbiome alterations associated with symptom severity and metabolomic shifts in a case-control cohort.
Fibromyalgia & Bile Acids
PAIN, 2022
Altered serum bile-acid profile in fibromyalgia is associated with specific gut microbiome changes and symptom severity
Identified associations between serum bile acid profiles, specific gut microbiome alterations, and symptom severity in a retrospective fibromyalgia cohort.
Fibromyalgia & Diet
IJERPH, 2022
Dietary Intake Is Unlikely to Explain Symptom Severity and Syndrome-Specific Microbiome Alterations in a Cohort of Women with Fibromyalgia
Demonstrated that dietary intake does not account for observed microbiome alterations, strengthening the interpretation of a disease-specific biological signal.
Mechanistic Foundation
Neuron, 2025
Mechanistic fibromyalgia evidence informing SomaBiome's clinical translation strategy
Foundational research providing mechanistic insights into the gut-brain axis and its relevance to chronic pain signaling and sensory processing.
We include select non-fibromyalgia publications that demonstrate cross-cohort reproducibility in chronic pain and causal microbiome-to-host mechanisms that inform our analytical approach.
While broader chronic-pain studies inform model development and cross-cohort robustness, SomaBiome's first clinical product is focused specifically on fibromyalgia.
Chronic Pain Generalization
Anesthesiology, 2025
Gut microbiome signatures in Complex Regional Pain Syndrome (CRPS)
Demonstrated reproducible microbiome signatures across independent cohorts and geographies, strengthening broader chronic-pain analytical robustness.
Mechanistic Validation
Gut, 2023
Gut microbiota influence anastomotic healing in colorectal cancer surgery through modulation of mucosal proinflammatory cytokines
Demonstrated causal links between gut microbiome composition and anastomotic healing. Identified Alistipes onderdonkii as a driver of leak risk and Parabacteroides goldsteinii as a protective factor modulating mucosal proinflammatory cytokines.
Selected coverage
- Nature News — "Baffling chronic pain eases after doses of gut microbes" (Apr 24, 2025) — https://doi.org/10.1038/d41586-025-01290-x
- Nature Outlook: Pain — "The gut microbiome and chronic pain" (Sep 25, 2024) — https://doi.org/10.1038/d41586-024-03006-z
Media coverage discusses peer-reviewed research and does not constitute endorsement or clinical validation of any product.
Performance & Translation
Published retrospective research cohorts support the biological signal and classifier development. Prospective clinical validation in real-world workflows remains the key next step.
Disclaimer: Performance metrics refer to retrospective analysis in research cohorts. Prospective clinical validation in real-world settings is the primary de-risking step. Not for consumer use.
See how this research translates into clinical workflow integration.